Zeria Pharmaceutical Co., Ltd. announced an increase in the year-end dividend for the fiscal year ending March 2026 to 25 yen per share, bringing the total annual dividend to 49 yen. The company emphasizes profits redistribution and maintains a policy of stable dividends.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4559","jir_company_name":"Zeria Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-05-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4559-20260508-02.pdf","jir_short_summary":"Zeria Pharmaceutical Co., Ltd. announced an increase in the year-end dividend for the fiscal year ending March 2026 to 25 yen per share, bringing the total annual dividend to 49 yen. The company emphasizes profits redistribution and maintains a policy of stable dividends.","jir_summary":"### Dividend Policy and Details\nZeria Pharmaceutical Co., Ltd. considers shareholder profit return as its top priority, with a basic policy of stable and continuous dividends. The year-end dividend for the fiscal year ending March 2026 is set at 25 yen per share, with a total annual dividend of 49 yen. This represents a 2 yen increase from the previous year's 47 yen. Dividend funds are sourced from retained earnings, and the increase reflects the company's performance and shareholder return preferences.\n\n### Future Shareholder Return and Corporate Strategy\nFollowing its fundamental profit distribution policy, Zeria Pharmaceutical Co., Ltd. aims to enhance shareholder value through continued stable dividends. The company will review dividend amounts and shareholder return measures based on performance trends. It emphasizes the importance of profit return to shareholders and strives for long-term corporate value enhancement.","jir_financial_highlights":"Dividend per Share: 25 Yen 00 Sen (Increase of 1 yen from the previous year's 24 Yen 00 Sen)\nTotal Dividend: 1,102 million yen (Increase from the previous year's 1,058 million yen)\nAnnual Dividend: 49 Yen 00 Sen (Increase of 2 Yen from the previous year's 47 Yen 00 Sen)","jir_category":"","jir_hashtags":"#ZeriaPharmaceutical, #Dividend, #JapaneseStocks","jir_key_figures":"Dividend per Share: 25 Yen\nAnnual Dividend: 49 Yen\nTotal Dividend: 1,102 million Yen","jir_meta_title":"\u3010Zeria Pharmaceutical\u3011Dividend Increase and Shareholder Return Policy\uff5cJune 2026","jir_meta_description":"Zeria Pharmaceutical announced an increase in the dividend for fiscal year 2026 to 25 yen per share, with the total annual dividend reaching 49 yen. The company emphasizes profit redistribution and plans to maintain stable dividends.","jir_og_title":"\u3010Zeria Pharmaceutical\u3011Dividend Increase and Shareholder Return Policy\uff5cJune 2026","jir_og_description":"Zeria Pharmaceutical plans to increase dividends in fiscal year 2026 and focuses on shareholder returns. The annual dividend is set at 49 yen, aiming to sustain stable payouts.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9548,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"dividend","footnotes":""},"sector":[],"importance":[],"class_list":["post-46205","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n